🏥
🏥 Health
Novo Nordisk Sues Eli Lilly Over Misleading Weight-Loss Drug Ads
Danish pharmaceutical company Novo Nordisk has sued US rival Eli Lilly, alleging that Lilly's advertisements mislead consumers about how the two companies' weight-loss products compare. The dispute centres on the fiercely competitive obesity drug market, where Novo Nordisk sells Ozempic and Wegovy while Eli Lilly markets Mounjaro and Zepbound. Novo Nordisk is seeking a preliminary injunction to block the contested ads.
More from Health
Poland's GUS reveals health spending data for 2023–2025
Interia Biznes · 40min ago
NSW to send mental health nurses instead of police to some psychiatric emergencies
The Guardian World · 3h ago
Energy drink industry funded research that downplayed risks of mixing alcohol with Red Bull
STAT News · 4h ago
Comments
No comments yet
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!